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ABSTRACT - RESUM 
CD19-TARGETED CAR T CELLS THERAPY 
Over the years, the scientific community has been studying and exploring different 
strategies to treat cancer using gene therapy techniques that have culminated in the 
development of an immunotherapy called Chimeric Antigen Receptor (CAR) T cells 
therapy. 
Recently, two different types of CAR T cell therapies have been approved to treat B cell 
malignancies by the FDA and the AEMPS: tisagenlecleucel (Kymriah®) and 
axicabtagene ciloleucel (Yescarta®), becoming an important paradigm shift due to their 
special characteristics. These medicines are autologous biological medicines where 
immune cells, concretely T lymphocytes, are collected from the blood of the patient, 
processed and sent to manufacturing facilities. There, gene-editing modification is 
performed through viral vectors in order to express certain chimeric antigen receptors in 
the cell membrane of the T lymphocytes. Here comes the key to the success of these 
revolutionary therapies: these artificial receptors are able to get linked and recognize 
specific antigen, CD19, that is expressed in the entire B-cell lineage. Once they 
recognize it, T-cell expansion, cytotoxic activity, releasing of cytokines and pro-
inflammatory substances happen and, therefore, anti-tumour effects are achieved.  
In addition, an analysis of the situation in our country related to these therapies will be 
performed: the Banc de Sang i Teixits (BST) plays an important role in the manufacturing 
process since they collect leukapheresis material, process it and cryopreserve it before 
it is shipped to manufacturing facilities and the other way around. 
Finally, current challenges of these therapies such as side effects and logistic aspects 
will be discussed. Furthermore, the possible future perspectives of these 
immunotherapies will be exposed. 
TERÀPIA AMB CÈL·LULES CAR-T CD19 
Durant els darrers anys, la comunitat científica ha investigat i explorat diferents 
estratègies per poder tractar el càncer mitjançant tècniques de teràpia gènica que han 
culminat en el desenvolupament d’una nova immunoteràpia anomenada teràpia de 
cèl·lules CAR T (T cell Chimeric Antigen Receptor). 
Recentment, la FDA i l’AEMPS han aprovat dues noves teràpies CAR T per al tractament 
de certes leucèmies i limfomes que afecten als limfòcits B: tisagenlecleucel (Kymriah®) 
i axicabtagen ciloleucel (Yescarta®), convertint-se en un complet canvi de paradigma 
degut a les seves característiques. Aquests nous fàrmacs són medicaments biològics 
d’ús autòleg procedents de l’extracció de limfòcits T de la sang del pacient, que es 
processen i s’envien als laboratoris elaboradors. En aquestes instal·lacions, els limfòcits 
T pateixen modificacions genètiques gràcies a vectors virals que conduiran a l’expressió 
d’un receptor específic a la membrana d’aquestes cèl·lules quimèriques. Aquest 
receptor d’antigen quimèric és el principal motiu de l’èxit d’aquestes immunoteràpies, ja 
que és capaç de reconèixer un antigen específic, el CD19, que es troba expressat en 
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tot el llinatge dels limfòcits B. Un cop l’antigen és reconegut, aquests limfòcits T 
modificats són activats i diversos mecanismes entren en acció, com per exemple el 
creixement de la població de limfòcits T, l’alliberació de citocines i substàncies pro-
inflamatòries, entre d’altres, amb l’objectiu final d’obtenir una robusta activitat citotòxica, 
i en conseqüència, efectes anti-tumorals. 
A més a més, en aquest treball es durà a terme un anàlisi de la situació i implementació 
d’aquestes teràpies en el nostre país, on el Banc de Sang i Teixits (BST) té un paper 
important. El BST participa en el procés d’elaboració dels fàrmacs ja que s’encarrega 
de la recol·lecció del material d’afèresi, del seu processament cel·lular i criopreservació 
abans de ser enviat a les instal·lacions de fabricació; així com en el camí invers. 
Finalment, seran tractats diversos conceptes com per exemple els reptes actuals sobre 
efectes adversos i logística, i també quines perspectives de futur té aquest tipus de 
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ABBREVIATIONS
ACD-A: Anticoagulant Citrate Dextrose 
solution A. 
ACT: Adoptive Cell Therapy. 
AEMPS: Agencia Española de 
Medicamentos y Productos Sanitarios. 
ALL: Acute Lymphoblastic Leukaemia. 
APC: Antigen-Presenting Cell. 
B7: actually B7.1 and B7.2 (also known 
as CD80/CD86). 
BCR: B-Cell Receptor. 
BST: Banc de Sang i Teixits. 
CAR: Chimeric Antigen Receptor. 
CD: Cluster of Differentiation. 
CH: constant region of Ig heavy chain. 
CL: constant region of Ig light chain. 
CNS: Central Nervous System. 
CR2: Complement Receptor type 2. 
CRES: CAR-T cell Related 
Encephalopathy Syndrome. 
CRS: Cytokine Release Syndrome. 
CTL: Cytotoxic T Lymphocyte. 
CTL019: tisagenlecleucel.  
DIN: Donation Identification Number. 
DLBCL: Diffuse Large B Cell 
Lymphoma. 
DMSO: Dimethyl Sulfoxide. 
FDA: Food and Drug Administration. 
FIN: Facility Identification Number. 
GADS: GRB2-related adaptor protein. 
GMP: Good Manufacturing Practices. 
GRB2: Growth Factor Receptor-Binding 
Protein 2. 
GVHD: Graft-Versus-Host Disease. 
HIV: Human Immunodeficiency Virus. 
HLA: Human Leucocyte Antigen. 
HSA: Human Serum Albumin. 
ICAM-1: Intercellular Adhesion 
Molecule-1. 
IFNg: g-interferon. 
IgA: Immunoglobulin A (also D, E, G and 
M). 
IL-2: Interleukin-2 (also 4, 5, 6, 13, 15 
and 17). 
ISBT: International Society of Blood 
Transfusion. 
ITAM: Immunoreceptor Tyrosine-based 
Activation Motif. 
JAK: Janus Kinases. 
KTE-C19: axicabtagene ciloleucel.  
LAT: Linker for Activation of T-cells. 
LEU13: also known as CD225. 
LFA-1: Lymphocyte Function-
Associated Antigen-1 (also Antingen-3). 
MAPK: Mitogen-Activated Protein 
Kinase. 
MHC: Major Histocompatibility Complex. 
MSCBS: Ministerio de Sanidad, 
Consumo y Bienestar Social. 
MZ: Marginal-Zone. 
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NFAT: Nuclear Factor of Activated T-
cells. 
PAMP: Pathogen-Associated Molecular 
Pattern. 
PBMC: Peripheral Blood Mononuclear 
Cell. 
PDK1: Pyruvate Dehydrogenase Kinase 
1. 
PKC: Protein Kinase C. 
PLCg1: Phospholipase Cg1. 
PMLBCL: Primary Mediastinal Large B-
Cell Lymphoma. 
PRR: Pattern Recognition Receptor. 
PSMA: Prostate-Specific Membrane 
Antigen. 
PTK: Protein Tyrosine Kinase. 
r/r: relapsed/refractory. 
scFv or Fv: single chain VH-VL antigen 
binding fragment. 
SEC: Single European Code. 
SLP-76: SH2-domain containing 
Leukocyte Protein of 76kDa. 
SNS: Sistema Nacional de Salud. 
STAT3: Signal Transducer and Activator 
of Transcription 3 (also STAT5). 
TAPA-1: also known as CD81. 
TCM: Central Memory T-cell. 
TCR: T-Cell Receptor. 
TEM: Effector Memory T-cell. 
TIL: Tumour-Infiltrating Lymphocytes. 
TNC: Total Nucleated Cell. 
TRUCK: T cell Redirected for Universal 
Cytokine-mediated Killing. 
VCAM-1: Vascular Cell Adhesion 
Molecule. 
VH: variable region of Ig heavy chain. 
VL: variable region of Ig light chain. 
VLA-4:  Very Late Antigen-4. 
ZAP-70: Zeta Chain-Associated Protein 
of 70kDa
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INTEGRATION OF DIFFERENT SCOPES 
CAR T cell therapy is a complex concept that requires possessing robust notions about 
different scientific fields in order to understand it completely. The main field of this final 
degree project is Biochemistry and Molecular Biology since this field establishes the 
fundamental bases on which this project is based on.  
However, in order to fully understand CAR T cell concept, the reader might need some 
knowledge of other fields of science so as to embrace the whole context where CAR T 
cell therapies take place. As a consequence, there are secondary fields that will be 
involved in this project, for instance Immunology, which is a science field that studies 
the immune system, its structure, function and importance, helping to contextualises 
several diseases related to immune system such as B cell malignancies.  
Regarding to these B cell malignancies, axicabtagene ciloleucel and tisagenlecleucel 
are immunotherapies indicated for the treatment of certain leukaemias and lymphomas, 
whose physiopathological mechanism is very attached to how these medicines act in our 
organism; that is why certain knowledge in Physiology and Physiopathology it is 
required.  
Finally, another scientific area of knowledge that can provide basic information to 
integrate, assimilate and comprehend the aspects discussed in this project is Cell 
Biology, which consists on the study of the cell, its composition, functions and main 
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INTRODUCTION 
Immune system 
The immune system is one of the most incredible and complex mechanisms to respond 
against infections and cancer. It is formed by different types of cells, tissues and 
molecules that work and collaborate to act coordinately in the immune response. 
Immune system must be capable of recognising, identifying and developing the correct 
defence mechanism in order to destroy foreign entities and prevent organ damage. 
The immune response is diverse and there are three different levels of immunity: external 
defensive barriers, innate response and adaptive immune response [1]. 
External defensive barriers 
When an infectious agent penetrates inside the human body and induces immune 
response is because the external defensive barriers have failed and the agent has been 
capable of making his way through and get into. This first level of defence is formed by 
physical, chemical and biological barriers [2]. Physical barriers are composed of skin 
surface and mucus secretions that cover and protect the epidermal layers of inner tracts 
of organs and systems that have access to the external environment, such as respiratory, 
digestive and reproductive systems. The function and importance of this physical 
defence are supported by chemical barriers, for example the buccal cavity contains 
salivary proteins like lysozyme that has antimicrobial and bactericidal functions [3]; 
another important example is the maintenance of specific pH levels in some crucial areas 
of the digestive system to avoid the entrance of pathogenic microorganisms. The third 
barrier is called biological barrier and it consists of the bacterial population that humans 
host inside certain organs like the gut (gut microbiota) and the presence of this huge 
number of microorganisms make the colonization of pathogenic bacteria difficult which, 
in turn, could lead to an infection [4]. 
Innate response 
The second level of immune response is called innate response: it is based on 
recognizing (through Pattern Recognition Receptors, PRRs) different molecular patterns 
and components (Pathogen Associated Molecular Patterns, PAMPs) that are associated 
to groups of pathogens because these structures have been conserved during millions 
of years of evolution. This innate response starts in the first place when pathogenic 
agents enter inside of the organism and this response remains activated during the next 
few days. 
The main components that take part in this response are macrophages, neutrophils 
and different types of proteins with bactericidal properties such as lysozyme and 
complement. Even though innate response is usually highly effective, some infectious 
agents are able to resist and avoid this first attack. If innate response is not enough to 
neutralize the agent, this response tries to contain and remain under control the hazard 
while the immune system is developing the next mechanism, adaptative response, a 
more specific strategy [1,2]. 
  2 
Adaptative response 
Adaptative response, also known as acquired or specific response, allows immune 
system to recognize specific pathogens and to develop a strategy to neutralize them. 
Adaptative response is mediated by B and T lymphocytes that develop different antigen 
receptors (B cell receptor -BCR- and T cell receptor -TCR-, respectively) located in their 
membranes that are highly specific and can recognize countless structures. This is 
possible because, unlike PRRs in innate response, the antigen receptors of adaptative 
immune response are formed by non-conserved and variable structures that suffer 
genetic recombination and that leads to the creation of millions of specific antigen 
receptors. That is the main reason why this third level of immune defence takes longer 
to achieve a functional and effective mechanism, mainly four or five days after innate 
response is initiated [1,2]. 
T lymphocytes 
Structure 
T-cells are a lymphocytes population with specific antigen 
receptor called TCR, that is made up by different chains. 
Actually, there are only two versions of this TCR receptor: 
TCRab (more common) and TCRgd (less common), but 
only one type is expressed in one T-cell. Indeed, TCR is a 
heterodimer formed by two non-identical polypeptide 
chains (a, b, g, and d) but the only functional combinations 
possible are ab and gd. Each chain is composed by two 
domains, variable domain (V) and constant domain (C), 
which have different functions each. Variable domain is 
essential for the antigen recognition mechanism; by 
contrast, the main function of the constant domain is being 
part of the transduction signal pathways that will active 
different mechanism [5]. 
In addition, T lymphocytes also have in their cell membrane 
the CD3 transmembrane protein that is a co-receptor 
complex that plays a significant part in the propagation of 
the signal. This co-receptor complex is made up by CD3g, 
CD3d and CD3e invariable chains, that have similar 
structures and characteristics, and CD3z. This fourth invariable chain (CD3z) is 
associated to the TCR structure in pairs (dimers) linked to each other through disulphide-
links. 
These structures, mainly CD3z but also CD3g, d and e, have immunoreceptor tyrosine-
based activation motifs (ITAMs): these motifs make the propagation of activation 
signals possible when they get phosphorylated in the moment the T-cell recognizes it 
and is activated by the presence of antigen [Fig. 1]. 
Functions 
T lymphocytes have different functions depending on what type of CD are presenting in 
their membrane cell: CD4 or CD8.  
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through an associated complex of transmembrane polypeptides 
(CD3) to th  interior of the T‐lymphocyte, instructing it t  
awaken from its slumbering G0 state and do something use-
ful – like becoming an effector cell. In all immunocompetent 
T‐cells, the TCR is noncovalently but still intimately linked 
with CD3 in a complex that, as current wisdom has it, may 
contain two heterodimeric TCR αβ or γδ recognition units 
closely apposed to one molecule of the invariant CD3 polypep-
tide chains γ and δ, two molecules of CD3ε, plus the disulfide‐
linked ζ–ζ dimer. The total complex therefore has the structure 
TCR2–CD3γδε2–ζ2 (Figure 4.8 and Figure 4.10b).
Similar to the BCR‐associated Ig–α/β heterodimer, the 
CD3 chains also contain one or more ITAMs and these motifs, 
once again, are instrumental in the propagation of activation 
signals into the lymphocyte. Upon encounter of the TCR with 
peptid –MHC, the ITAMs within the CD3 complex become 
phosphorylated at tyrosine residues; these then act as a plat-
form for the recruitment of a veritable multitude of phospho-
tyrosine‐binding proteins that further disseminate the signal 
throughout the T‐cell. It is here that the role of the CD4 and CD8 
co‐receptors becomes apparent; phosphorylation of the ITAMs 
within the CD3 ζ (zeta) chain is accomplished by the Lck 
tyrosine kinase that, you may recall, is associated with the 
 cytoplasmic tails of CD4 and CD8 (Figure 4.7 and Figure 4.8). 
In mice, either or both of the ζ chains can be replaced by a 
splice variant from the ζ gene termed η. The ζ chain also asso-
ciates with the FcγRIIIA receptor in natural killer (NK) cells 
































































Figure  4.10 The T‐cell receptor (TCR)/CD3 complex. The TCR resembles the immunoglobulin Fab antigen‐binding fragment in structure. 
The variable and constant segments of the TCR α and β chains (VαCα/VβCβ), and of the corresponding γ and δ chains of the γδ TCR, 
belong structurally to the immunoglobulin‐type domain family. (a) In the model the α chain CDRs are colored magenta (CDR1), purple 
(CDR2), and yellow (CDR3), whilst the β chain CDRs are cyan (CDR1), navy blue (CDR2) and green (CDR3). The fourth hypervariable 
region of the β chain (CDR4), which constitutes part of the binding site for some superantigens, is colored orange. (Reproduced from 
Garcia K. et al. (1998) Science 279, 1166; with permission.) The TCR α and β CDR3 loops encoded by (D)J genes are both short; the 
TCR γ CDR3 is also short with a narrow length distribution, but the δ loop is long with a broad length distribution, resembling the Ig light 
and heavy chain CDR3s, respectively. (b) The TCRs may be expressed in pairs linked to the CD3 complex. Negative charges on trans-
membrane segments of the invariant chains of the CD3 complex contact the opposite charges on the TCR Cα and Cβ chains conceivably 
as d picted. (c) The cytoplasmic dom ins of the CD3 peptide chains contain immunoreceptor tyrosine‐based activation motifs (ITAMs; see 
BCR, Figure 4.4) that contact src protein tyrosine kinases. Try not to confuse the TCR γδ and the CD3 γδ chains.
Figure 1. TCR and CD3 co-receptor structure 
[5]. 
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- The ones presenting CD4 are called Th (T-cell helper) because their main 
purpose and function is to interact with B-cell and other cells (monocytes and 
macrophages) and to promote activation of macrophages and destruction of 
pathogens, the activation and differentiation of T-cells and the synthesis of 
immunoglobulins. These final effects of the Th’s actions can be accomplished by 
the interaction of accessory molecules and by the secretion of cytokines, a broad 
group of small proteins realized by T-cells to interact and communicate between 
different cells. Indeed, there are three subsets in T-cell helper population: Th1, 
Th2 and Th17 cells. The main difference between them is what molecules and 
substances they secrete. For example, Th1 cells secrete interferon gamma 
(IFNg) to lead directly the activation of cytotoxic T-cells and macrophages in order 
to neutralize intracellular pathogens, Th2 cells secrete IL-4, IL-5 and IL-13 to 
activate B-cell antibody response against multicellular parasites. Finally, Th17 
cells make neutrophils and B-cells response effective against extracellular 
bacteria and fungi by secreting IL-17 [2,5]. 
- T lymphocytes subtype that express CD8 in their cytoplasmatic membrane are 
known as cytotoxic T-cells (Tc or CTL). When a Tc cell is activated, it promotes 
the proliferation and differentiation of CTLs and the synthesis and secretion of 
perforin and granzymes, which are cytotoxic molecules that are able to lysate 
cells infected by virus or cancerous cells. 
Once an antigen is recognized for the first time by naïve T-cells, these antigen-specific 
T lymphocytes undergo clonal expansion and become able to secrete effector cytokines 
and trigger cytotoxic activity in a phase that is known as activation phase. As a 
consequence of this activation, the antigen is cleared and these effector T-cells are no 
longer useful so it starts the second phase, the contraction phase, where this Ag-
specific cells die by apoptosis or by reducing growth factor levels. Meanwhile, a small 
percentage of this activated T cells are able to avoid this contraction phase and will 
become the reservoir of memory T cells. Therefore, it starts the third phase called the 
memory phase where these survivor T cells will become memory T cells with special 
characteristics: memory T cells are formed at higher frequencies than naïve T cells and 
possess rapid clonal proliferation and activation, among other traits [6]. 
Basically, there are two different subsets of memory T cells, that differ in the expression 
of certain surface proteins, areas of the organism where it is possible to find them and 
their function. For instance, long-lived central memory T cells (TCM) home secondary 
lymphoid organs and can rapidly proliferate and differentiate into cells with effector 
functions in response to antigenic stimulation. In contrast, effector memory T cells (TEM) 
are found in inflamed peripheral tissues and possess immediate effector functions, so 
they provide to us a reactive memory, unlike TCM that mediate protective immunity and 
they have long-term persistence [7]. 
Activation 
First of all, it is important to mention that, in order to recognize and develop an effective 
response, T-cells can only interact and recognize antigens when they are presented by 
MHC molecules by antigen presenting cells (APCs). Indeed, there are two different 
types of MHC molecules, MHC class I and class II: CD4 on Th cells acts as a co-
receptor for MHC II and makes the interaction between TCR and antigen-MHC complex 
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more stable; CD8 on cytotoxic T-cells helps in the same way to the union of TCR and 
peptide-MHC class I complex [Fig. 2]. 
Secondly, the interaction between MHC molecules and 
TCR is not enough for T-cells to develop a proper response 
because the association’s affinity TCR-antigen-MHC is low 
and insufficient. As a result of these low affinity, it requires 
the interaction of other molecules that will increase the 
affinity and will stabilize this association: these molecules 
are known as accessory molecules. Most important 
examples of this intercellular adhesion molecules are 
CD2/LFA-3, VLA-4/VCAM-1 and LFA-1/ICAM-1. 
Finally, when TCR and MHC-peptide complex interact 
between them and CD4/CD8 and accessory molecules of 
intercellular adhesion stabilize their interaction, that 
provides what it is known as signal 1. This stimulation of 
TCR by MHC-peptide complex it is not enough and T-cell must be exposed to an 
engagement of CD28 (on the T-cell) and B7 (also known as CD80/CD86) co-stimulatory 










Amplification of the signal: different pathways 
Once TCR-MHC-peptide complex is done and stabilized by CD4 or CD8, these co-
receptor for MHC intimately associated with Lck, a protein tyrosine kinase (PTK), that is 
able to phosphorylate the three small areas called ITAMs that the two CD3z chains have 
in their cytoplasmatic tails. As a result of this phosphorylation, it is generated bindings 
sites for ZAP-70 to come and get activated. Due to this activation, ZAP-70, which actually 
is a PTK, phosphorylates two adaptor-proteins: LAT and SLP-76. These activated 
adaptor-proteins will generate triggered different signalling pathways.  
- LAT protein will be used as a platform where another adaptor protein will get 
linked through these phosphotyrosine residues. For example, PLCg1 and GRB2, 
that will have an important role in phosphatidylinositol and Ras/MAPK 
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ligand (whether this is a growth factor, a hormone, or an  antigen) 
results in conformational or other changes within the receptor 
that promotes recruitment of cytoplasmic adaptor proteins to 
the portion of the receptor exposed to the cytoplasm. Because 
many plasma membrane receptors are protein kinases, or can 
recruit protein kinases upon engagement with their specific 
ligands, stimulation of such receptors typically results in phos-
phorylation of regions within the receptor in contact with the 
cytoplasm (i.e., the cytoplasmic tail) or of associated proteins.
In the case of the B‐ and T‐cell receptors (BCR and TCR), 
the receptors themselves do not have any intrinsic enzymatic 
activity but are associated with invariant accessory molecules 
(the CD3 γδε and ζ chains in the case of the TCR, and the Ig‐αβ 
complex in the case of the BCR) that can attract the attentions 
of a particular class of kinases. Central to this attraction is the 
presence of special motifs called ITA s (immunoreceptor 
tyrosine‐based activation motifs) within the cytoplasmic tails 
of these accessory molecules (see also Chapter 4). Phosphorylation 
of ITAMs at tyrosine residues –  in response to TCR or BCR 
stimulation  –  enables these motifs to interact with adaptor 
 proteins that have an affinity for phosphorylated tyrosine motifs, 
thereby initiating signal transduction. We will deal, in turn, with 
the signaling events that take place upon encounter of a T‐cell or 
a B‐cell with antigen.
T‐lymphocytes and antigen‐presenting 
cells interact through several pairs 
of accessory molecules
Before we delve into the nuts and bolts of TCR‐driven signaling 
events, it is important to recall that T‐cells can only recognize 
antigen when presented within the peptide‐binding groove 
of  major histocompatibility complex (MHC) molecules. 
Furthermore, while the TCR is the primary means by which 
T‐cells interact with the MHC–peptide complex, T‐cells also 
express co‐receptors for MHC (either CD4 or CD8) that define 
functional T‐cell subsets. Recall that CD4 molecules act as 
co‐receptors for MHC class II and are found on T‐helper cell 
populations that provide “help” for activation and maturation 
of B‐cells and cytotoxic T‐cells (Figure 7.1). CD8 molecules act 
as co‐receptors for MHC class I molecules and are a feature of 
cytotoxic T‐cells that can kill virally infected or precancerous 
cells (Figure 7.1). Note, however, that the affinity of an indi-
vidual TCR for its specific MHC–antigen peptide complex is 
relatively low (Figure 7.2). Thus, a sufficiently stable associa-
tion with an antigen‐presenting cell (APC) can only be achieved 
by the interaction of several complementary pairs of accessory 
 molecules such as LFA‐1/ICAM‐1, CD2/LFA‐3, and so on 
(Figure 7.3). These adhesion molecules enable T‐cells to associate 
with DCs and other APCs for the purposes of inspecting the 
peptides being presented within MHC molecules (Figure 7.4). 
However, these molecular couplings are not necessarily 
 concerned with intercellular adhesion alone; some of these 
interactions also provide the necessary co‐stimulation that is 

















Figure 7.1 Helper and cytotoxic T‐cell subsets are restricted by 
MHC class. CD4 on helper T‐cells acts as a co‐receptor for MHC 
class II and helps to stabilize the interaction between the TCR and 
peptide–MHC complex; CD8 on cytotoxic T‐cells performs a 











Figure 7.2 The relative affinities of molecular pairs involved in 
interactions between T‐lymphocytes and cells presenting antigen. 
The ranges of affinities for growth factors and their receptors, and 
of antibodies, are shown for comparison. (Adapted from Davies 
M.M. and Chien Y.‐H. (1993) Current Opinion in Immunology 5, 45. 
Reproduced with permission of Elsevier.)
Figure 2. CD8 and CD4's important role in TCR-
antigen-MHC complex [5]. 
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Unstimulated lymphocytes are typically nonadherent but 
rapidly adhere to extracellular matrix components or other cells 
(such as APCs) within seconds of encountering chemokines or 
antigen. Integrins such as LFA‐1 and VLA‐4 appear to be 
 particularly important for lymphocyte adhesion. The ease with 
which lymphocytes can alter their adhesiveness seems to be 
related to the ability of integrins to change conformation; from 
a closed, low‐affinity state to a more open, high‐affinity one 
(Figure 7.5). Thus, upon encounter of a T‐cell with an APC 
displaying an appropriate MHC–peptide complex, signals 
routed through the TCR complex ensure that the affinity of 
LFA‐1 for ICAM‐1 is rapidly increased and this helps to stabilize 
the interaction between the T‐cell and the APC. This complex 
has come to be known as the immunological synapse. Activation 
of the small GTPase Rap1 by TCR stimulation appears to 
 contribute to the rapid change in integrin adhesiveness. How 
Rap1 achieves this remains somewhat uncertain, but it is likely 
that modification of the integrin cytoplasmic tail serves to trigger 
a conformational change within the integrin extracellular 





















Figure  7.3  Activation of resting T‐cells. Interaction of co‐stimulatory molecules leads to activation of resting T‐lymphocyte by antigen‐pre-
senting cell (APC) on engagement of the T‐cell receptor (TCR) with its antigen–MHC complex. E gagement of the TCR signal 1 wi hout 
accompanying co‐stimulatory signal 2 leads to anergy. Note, a cytotoxic rather than a helper T‐cell would, of course, involve coupling of 
CD8 to MHC class I. Signal 2 is deliv r d to a resting T‐cell prim rily through engagement of CD28 on the T‐cell by B7.1 or B7.2 on the 
APC. ICAM‐1, intercellular adhesion molecule‐1; LFA‐1, lymphocyte function‐associated molecule‐1; VCAM‐1, vascular cell adhesion 





Figure  7.4  Interaction between T‐cells and dendritic cells. Scanning electron microscopy analysis of DC–T‐cell interactions within a 
3 ‐D collagen matrix. (Source: Gunzer M. et al. (2004) Blood 104 , 2801–2809. Reproduced with permission of American Society of 
Hematology.)
Figure 3. Activation of T lymphocytes [5]. 
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pathways respectively. In addition, LAT activated protein will make possible the 
recruitment of GADS, an adaptor protein related to SLP-76.  
- SLP-76, that is intimately linked to GADS, will generate cytoskeletal 
modifications. 
 
On one hand, phosphatidylinositol pathway will lead to an increase of intracellular 
Ca2+ concentration that will activate PKC and calcineurin whose function is, among 
other things, the activation of transcription factors, such as NFkB and NFAT, that will 
trigger IL-2 production and other molecules implicated in T-cell activation. 
On the other hand, Ras/MAPK pathway will lead to the formation of two heterodimers 
transcription factors known as Fos/Jun related to IL-2 production, among another 
essential transcription factors for T-cell proliferation [5] [Fig. 4]. 
B lymphocytes 
Structure 
B-cells are a group of lymphocytes whose receptor is called BCR: it has the ability to 
recognize soluble and particulate antigens through its structure. B-cells receptor complex 
is made up by a membrane-bound antibody, Ig-a (CD79a) and Ig-b (CD79b). 
The membrane-bound immunoglobulin’s structure 
consists of four polypeptide chains, two heavy 
chains (H) and two light chains (L), connected 
between them by disulphide bridges. Both different 
types of chains have in their structure one variable 
region (VH and VL) and one constant region (CH and 
CL). Indeed, immunoglobulins are formed by three 
fragments: two Fab, that are able to recognize 
antigens and get united, and Fc, which does not 
have the ability to interact with antigens. There are 
five types of antibodies or immunoglobulins: IgG, 
IgM, IgE, IgD and IgA, based on their different 






















































Figure  7.8  Signaling events downstream of T‐cell receptor (TCR) engagement. (a) Engagement of the TCR with the correct peptide–MHC combination leads to CD4/
CD8 recruitment to the TCR complex through interactions with MHC on the antigen‐presenting cell (APC) (note that, for simplicity, co‐stimulation between B7 and 
CD28 is not depicted). Because CD4 and CD8 are constitutively associated with the Lck kinase, this brings Lck into close proximity to the ITAMs within the CD3 
co‐receptor complex. Lck then phosphorylates CD3ζ on multiple sites, that creates binding sites for recruitment of the ZAP‐70 kinase. (b) ZAP‐70 recruitment to the 
CD3 co‐receptor complex leads to its phosphorylation and activation by Lck. Active ZAP‐70 then propagates TCR signals through phosphorylation of LAT at several 
sites. Phosphorylated LAT serves as a platform for recruitment of multiple signaling complexes, as depicted. (c) Molecules recruited to LAT instigate three main 
signaling cascades, as depicted, which cooperatively achieve T‐cell activation. See main text for further details.
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Ig‐α and Ig‐β each contain a single ITAM (immunorecep-
tor tyrosine‐based activation motif) within their cytoplasmic 
tails and this motif contains two precisely spaced tyrosine 
r esidues that are central to their signaling role (Figure 4.4 and 
Figure  4.5). Engagement of the BCR with antigen leads to 
rapid phosphorylation of the tyrosines within each ITAM, by 
kinases associated with the BCR, and this has the effect of 
c reating binding sites for proteins that have an affinity for 
phosphorylated tyrosine residues. In this case, a protein kinase 
called Syk becomes associated with the phosphorylated Ig‐α/‐β 
heterodimer and is instrumental in coordinating events that 
culminate in entry of the activated B‐cell into the cell cycle to 
commence clonal expansion. We will revisit this topic in 
Chapter 7 where the details of the BCR signal transduction 
cascade will be elaborated upon in greater detail.
Specific antigen drives formation of B‐cell 
receptor microclusters
Recent studies suggest that many of the BCRs do not freely 
diffuse within the plasma membrane with their associated 
Ig‐α/β heterodimers, but are constrained within specific zones 
by the underlying actin cytoskeleton. The actin cytoskeleton 
does not make contact with the BCR directly but corrals the 
receptor into confinement zones through interaction with 
membrane ezrin. There is a good reason for this confinement, 
as this appears to be required to prevent spontaneous forma-
tion of BCR microclusters. These appear to be the structures 
that are capable of transmitting signals into the B‐cell that rep-
resents an activation stimulus. BCR microclusters are made up 
of 50–500 BCR molecules and have been visualized on the 
surface of B‐cells using advanced microscopy techniques. 
Indeed, mere depolymerization of the actin cytoskeleton 
appears to be sufficient to permit weak B‐cell activation signals 
to occur spontaneously, without any requirement for antigen, 
suggesting that cytoskeleton‐based confinement is necessary 
and acts as a “safety catch” on BCR triggering. Indeed, weak 
background or “tonic” BCR signals appear to be necessary for 
B‐cell development, as interference with this situation results 
in death of developing B‐cells. Presumably a small fraction of 
the BCR pool that is freely diffusible within the plasma 
m embrane provides this tonic signaling.
B‐cell activation appears to require that many BCRs become 
dislodged from their confinement zones to become recruited 
into microclusters, an event that very recent evidence suggests 
is achieved through antigen‐induced conformational changes 
within the antibody constant region that permits self‐association 
within the membrane. More effective BCR stimulation is also 
achieved through cross‐linking of the BCR with its co‐receptor 
complex, which is discussed below. B‐cell activation through 
BCR stimulation alone is possible, but the former tends to lead 
to low‐affinity IgM production and is far less p referable to 
co‐stimulation via the BCR co‐receptor complex.
There is also a growing appreciation that while B‐cells can 
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Figure 4.4 Model of B‐cell receptor (BCR) complex. The Ig‐α/Ig‐β 
heterodimer is encoded by the B‐cell‐specific genes mb‐1 and 
B29, respectively. Two of these heterodimers are shown with the 
Ig‐α associating with the membrane‐spanning region of the IgM μ 
chain. The Ig‐like extracellular domains are colored blue. Each 
tyrosine (Y)‐containing box possesses a sequence of general 
structure Tyr.X2.Leu.X7.Tyr.X2.Ile (where X is not a conserved 
residue), referred to as the immunoreceptor tyrosine‐based 
activation motif (ITAM). On activation of the B‐cell, these ITAM 
sequences act as signal transducers through their ability to 
associate with and be phosphorylated by a series of tyrosine 
kinases. Note that while a κ light chain is illustrated for the surface 









Figure 4.5 B‐cell receptor clustering drives activation. Activation 
of the BCR complex through antigen engagement results in signal 
propagation as a consequence of phosphorylation of the 
intracellular ITAMs within the Ig‐α/Ig‐β heterodimer.
Figure 5. B-cell receptor complex [5]. 
Figure 4. Amplification of the signal leading to different pathways [5] 
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Transmembrane immunoglobulin’s cytoplasmatic tail is only a few amino acids long so 
it is not capable of contain activation motifs to develop a proper response and its 
propagation. Therefore, an association with transmembrane proteins is necessary since 
their cytoplasmic structure is long enough to possess ITAMs and transmit signals from 
the BCR to the cell interior. These transmembrane proteins are Ig-a and Ig-b, also known 
as CD79a and CD79b respectively and they are associated with BCR in two 
heterodimers (Ig-a/Ig-b), linked between them by disulphide bridges [5] [Fig. 5]. 
Functions 
B-cells provide to the immune system essentials functions: binding to antigen, increase 
antibody production and execute humoral response. Moreover, they are able to process 
antigens, fragment them and present this portions to T-cells, in order to achieve B-cell 
full activation and develop a complex immune response. 
There are three fundamental subtypes of B-cells, depending on the area they are found 
and what type of receptors they express on their surface. B2 cells, also known as 
follicular B-cells because they are found inside lymphoid follicles of the spleen and lymph 
nodes, are capable of synthesizing highly specific monoreactive BCRs. Usually, they will 
need the presence of helper T-cells to develop high-affinity antibodies against antigens, 
which are known as thymus-dependent antigens. B1 cells and marginal zone B-cells 
(MZ), that express low specific polyreactive BCRs in their surfaces that recognize 
multiple evolutionarily conserved fragments of pathogenic antigens and this recognition 
is via thymus-independent antigen. As a result, they produce low-affinity antibodies that 
will be useful to provide rapid response and protection because, unlike the antibodies of 
B2 cells, they do not require much time to get synthesized because of their low-affinity. 
These two subtypes in B-cell will be found in different areas of the organism, such as the 
skin, the mucosa and the marginal zone of the spleen [5]. 
Basis of B-cell activation 
Main tools in B-cells, in order to achieve their activation, may differ depending on how 
they are being activated: thanks to Th cells antigen presentation or by themselves. Even 
though this could lead to slight differences, the bases of the mechanisms used are similar 
and all of them drive these B-cells to their cell cycle and stimulate their activity. 
First, B-cells activation starts with the interaction between antigen and the membrane-
bound antibody; this connection will lead to the phosphorylation of the tyrosine residues 
in the ITAMs present in the BCR cytoplasmatic tail (Ig-a and Ig-b heterodimer’s tails). 
This first phosphorylation will trigger the B-cell signalling pathway, where many proteins 
with different roles will provide binding sites, phosphorylation, recruitment and activation 
of certain kinases and protein complex that will end by class switching, clonal expansion 
and differentiation of the B-cells. 
As T-cells do, B-cells also need two co-stimulation signals to achieve an effective 
response: 
1. First way of co-stimulation in B-cells activation is provided by the co-receptor 
complex when BCR recognizes and interacts tightly with the antigen. Actually, 
this co-receptor complex is a tetrameric protein complex made up by LEU13 
(CD225), CD81 (TAPA-1), CD19 and CD21 (CR2). CD21, also known as CR2, 
will be useful in engaging with molecules such as complement (that comes from 
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innate response). In addition, CD19 is a transmembrane protein 
exclusive of B-cells that will be hosting several binding sites and 
phosphorylation items, similar function of LAT complex in T-cell 
activation. This protein will be crucial in the discussion of this 
project [Fig. 6]. 
2. Second co-stimulatory signal comes from the interaction of T 
and B cells after B-cell activation by transmembrane 
immunoglobulin-antigen bounding. Indeed, this second form of 
stimulation takes place by the engagement of CD40 ligand 
(located in T-cell membrane surface) and CD40 on the B-cell. B-
cell recognizes, gets activated and internalizes the antigen while 
T-cell is being activated and becoming Th thanks to dendritic cells antigen 
presentation. Once B-cell is presenting the antigen (previously internalized) in 
their surface (by MHC class II proteins), this T helper cell is able to recognize it, 
co-stimulate B-cell and, as a result, B-cell will undergo clonal expansion and 






Immunotherapy and cancer 
Immunotherapy, also known as biological therapy, is one of the most recent and 
revolutionary ways of treating cancer nowadays. The principal aim of immunotherapy is 
helping the immune system of the patient to increase and improve his immune response 
against cancer cells. As it has been discussed before, human immune system possesses 
the necessary tools to kill cancer cells and suppress tumour developing. However, are 
cancer cells able to survive and become a tumour in spite of being surrounded by 
immune cells such as T-cells, macrophages and B-cells? This inefficacy and failing of 
immune system is known as Hellström paradox, but in last decades the answers have 
been clearing out: cancer cells are able to express and produce inhibitory molecules and 
proteins to avoid immune system and escape from immune surveillance [8-10]. 
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T‐cell signaling pathway, activated PLCγ2 initiates a pathway 
that involves hydrolysis of PIP2 to generate diacylglycerol and 
inositol trisphosphate and results in increases in intracellular 
calcium and PKC activation (Figure 7.28). PKC activation, in 
turn, results in activation of the NFκB and JNK transcription 
factors and increased intracellular calcium results in NFAT 
activation, just as it does in T‐cells.
The Vav family of guanine nucleotide exchange factors 
consists of at least three isoforms (Vav‐1, ‐2, and ‐3) and is 
known to play a crucial role in B‐cell signaling through activa-
tion of Rac1 and regulating cytoskeletal changes after BCR 
cross‐l nking; Vav‐1‐deficient B‐cells are defective in prolifera-
tion associated with cross‐linking of the BCR (Figure 7.27).
The BCR cross‐linking model seems appropriate for an 
understanding of stimulation by type 2 thymus‐i dependent 
antigens, as their repeating determinants ensure strong binding 
to, and cross‐linking of, multiple Ig receptors on the B‐cell sur-
face to form aggregates that persist owing to the long half‐life 
of the antigen and sustain the high intracellular calcium needed 
for activation. On the other hand, type 1 T‐independent anti-
gens, such as the T‐cell polyclonal activators, probably bypass 
the specific receptor and act directly on downstream molecules 
such as diacylglycerol and protein kinase C, as Ig‐α and Ig‐β 
are not phosphorylated.
B‐cells require co‐stimulation via the B‐cell  
co‐receptor complex for efficient activation
Similar to T‐cells, B‐cells also require two forms of co‐stimulation 
to mount efficient effector responses. One form of co‐
stimulation takes place at the point of initial encounter of the 
BCR with its cognate antigen and is provided by the B‐cell 
co‐receptor complex that is capable of engaging with molecules 
such as complement that may be present in close proximity to 
the specific antigen recognized by the BCR. The other form of 
co‐stimulation required by B‐cells takes place after the initial 
encounter with antigen and is provided by T‐cells in the form 
of membrane‐associated CD40 ligand that engages with 
CD40 on the B‐cell. This form of co‐stimulation requires that 
the B‐cell has internalized antigen, followed by processing and 
presentation on MHC class II molecules to an appropriate 
T‐cell. If the B‐cell is displaying an MHC–peptide combination 
recognized by the T‐cell, the latter will be stimulated to pro-
duce cytokines (such as IL‐4) as well as provide co‐stimulation 
to the B‐cell in the form of CD40L. We will consider the 
nature of the co‐stimulatory signals provided by the B‐cell co‐
receptor complex here and deal with CD40L‐based co‐stimulation 
in a separate section below.
The mature B‐cell co‐receptor complex (Figure  7.29) is 
composed of four components: CD19, CD21 (complement 
receptor type 2, CR2), CD81 (TAPA‐1), and CD225 (LEU13, 
interferon‐induced transmembrane protein 1). CR2 is a recep-
tor for the C3d breakdown product of complement and its 
presence within the BCR co‐receptor complex enables a 
 component of the innate immune response (complement) to 
synergize with the BCR to productively activate B‐cells. 
Imagine a bacterium that has activated complement and has 
become coated with the products of complement activation, 
including C3d. If the same bacterium is subsequently captured 
by the BCR on a B‐cell, there is now an opportunity for CR2 
within the BCR co‐receptor complex to bind C3d, which 
effectively means that the B‐cell now receives two signals 
simultaneously. Signal 1 comes via the BCR and signal 2 via 
the co‐receptor complex. So how does simultaneous engage-
ment of the co‐receptor complex and the BCR lead to enhanced 
B‐cell activation?
Well, the answer is that we don’t know for sure, but it is 
clear that CD19 plays an especially important role in this 
process. CD19 is a B‐cell‐specific transmembrane protein 
that is expressed from the pro‐B‐cell to the plasma‐cell stage 
and possesses a relatively long cytoplasmic tail containing 
nine tyrosine residues. Upon B‐cell receptor stimulation, the 
cytoplasmic tail of CD19 undergoes phosphorylation at sev-
eral of these tyrosine residues (by kinases associated with the 
BCR) that creates binding sites on CD19 for several proteins, 
including the tyrosine kinase Lyn, Vav, and phosphatidylino-
sitol 3‐kinase (PI3K). CD19 plays a role as a platform for 
recruitment of several proteins to the BCR complex 
(Figure 7.28), much in the same way that LAT functions in 
TCR activation.
Vav is recruited to CD19 upon phosphorylation of the 
latter by Lyn and, along with PI3K that is also recruited to 
CD19 as a result of Lyn‐mediated phosphorylation 
(Figure 7.28), plays a role in the activation of the serine/thre-
onine kinase Akt; the latter may also enhance NFAT activa-





Figure 7.29 The B‐cell co‐receptor complex provides co‐stimula-
tory signals for B‐cell activation through recruitment of a number 
of signaling molecules, including phosphatidylinositol 3‐kinase 
and Vav, which can amplify signals initiated through the B‐cell 
receptor. On mature B‐cells, CD19 forms a tetrameric complex 
with three other proteins: CD21 (complement receptor type 2), 
CD81 (TAPA‐1), and CD225 (interferon‐induced transmembrane 
protein 1) (LEU13). See also Figure 4.6.
Figure 6. B-cell co-receptor 
complex [5]. 
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(glycogen synthase kinase 3) on NFAT. Because GSK3 can 
also phosphorylate and destabilize Myc and cyclin D, which 
are essential for cell cycle entry, Akt activation also has 
p ositive effects on proliferation of activated B‐cells.
Similar to the role that CD28 plays on T‐cells, the B‐cell 
co‐receptor amplifies signals transmitted through the BCR 
approximately 100‐fold. As we have discussed above, because 
CD19 and CR2 (CD21) molecules enjoy mutual association, 
this can be brought about by bridging the Ig and CR2 recep-
tors on the B‐cell surface by antigen–C3d complexes bound to 
the surface of APCs. Thus, antigen‐induced clustering of the 
B‐cell co‐receptor omplex with th  BCR lowers the threshold 
for B‐cell activation by bringing kinases that are associated 
with the BCR into close proximity with the co‐receptor com-
plex. The action of these kinases on the co‐receptor complex 
engages signaling pathways that reinforce signals originating 
from the BCR.
B‐cells also require co‐stimulation  
from T‐helper cells
Just as T‐cells require co‐stimulatory signals from DCs in the 
form of B7 ligands for productive activation (Figure  7.3), 
T‐dependent B‐cells also require o‐stimulation from T‐
helper cells in order to cross the threshold r quired for clonal 
expansion and differentiation to effector cells (Figure 7.24). 
The sequence of events goes much like this. Upon encountering 
cognate antigen through direct binding to a microorganism, 
the BCR undergoes the initial activation events described 
above. This culminates in the internalization of the BCR, 
along with captured antigen, which is then processed and 
presented on MHC class II molecules (Figure  7.30). To 
continue the process of maturation to either a plasma cell or 
a memory cell, the B‐cell must now encounter a T‐cell capa-
ble of recognizing one of the antigenic peptides the B‐cell is 
now presenting from the antigen it has internalized. Note 
that this need not be the same epitope recognized by the 
B‐cell to undergo initial activation. Upon encountering a 
T‐cell with the appropriate TCR, the B‐cell provides stimu-
lation to the T‐cell in the form of MHC–peptide as well as 
co‐stimulatory B7 signals (Figure 7.30). In turn, the T‐cell 
upregulates CD40 ligand (CD40L) that can provide essen-
tial co‐stimulation to the B‐cell, enabling the latter to 
become fully activated and undergo clonal expansion and 
class switching. If CD40L help is not forthcoming, B‐cells 
rapidly undergo apoptosis and are eliminated. This help is 
provided by a special class of T‐cell called a follicular helper 
T‐cell, a distinct branch of CD4+ T‐cells that express the 
cell surface receptor CXCR5, which targets them to B‐cell 
follicles in the secondary lymphoid organs. Thus, B‐cells 
and T‐cells provide mutual co‐stimulation as a means of 
reinforcing their initial activation signals (Figure 7.30). In 
effect, the B‐lymphocyte is acting as an APC and, as men-
tioned above, it is very efficient bec us  of its ability to con-
centrate the antigen by focusing onto its surface Ig. 
Nonetheless, although a preactivated T‐helper can mutually 
CD28
B-cell activation and
internalization of antigen 

















Figure 7.30 CD40–CD40L‐dependent B‐cell co‐stimulation by a ‐helper cell. Independently activat d T‐ and B‐cells can interact if t e B‐
cell is presenting the correct peptide–MHC complex sufficient for stimula io of the T‐cell. Successful antigen presen ati n by a B‐cell o 
an activated T‐helper cell results in CD40L‐dependent co‐stimulation of the B‐cell as well as the provision of cytokines, such as IL‐4, by 
the T‐cell that are essential for class switching, clonal expansion and differentiation to effector cells.
Figure 7. CD40-CD40L depend nt B-cell co-stimul tion [5]. 
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Nowadays, immunotherapy is in constant developing and investigating new techniques 
and strategies to treat cancer. Up to date, it is possible to classify them this way: 
- Virus therapy: there are certain viruses that have been modified in the laboratory 
with the purpose of infecting cancer cells and making them express viral antigens 
in their surface to become more visible for the immune system. Another strategy 
is modifying viruses so they can provoke the lysis of cancer cells. 
- Checkpoint inhibitors: these agents stimulate the immune system by reducing 
apoptotic lymphocytes death rates. 
- Monoclonal antibodies: they are made in the laboratory and modified in order to 
detect certain parts of cancer cells and kill them. 
- Cancer vaccines: introducing inside the organism fragments of cancer cells 
helps, in some cases, to prevent and even treat cancer. 
- Cytokines: substances secreted by immune system that help to stimulate and 
activate the response against cancer cells. 
- Immunomodulators: chemical substances that are able to interact with B-cells, T-
cells and other components of immune system and help them to increase their 
interaction and cooperation, producing a more effective response. 
- Chimeric Antigen Receptor (CAR) T-cell therapy: this type of immunotherapy has 
been developing for the latest years with satisfactory results in different types of 
blood cancer such as acute lymphoblastic leukaemia (ALL). This novel 
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OBJECTIVES 
The main purpose of this final degree project is to evaluate the current situation of 
immunotherapy in Spain, focusing on two new antineoplastic agents recently authorized, 
Yescarta® and Kymriah®. 
1. To explain how immunotherapy has evolved into developing CAR-T cells 
treatment. 
2. To show all the steps that follow manufacturing CAR-T cells, from collecting T-
cells from the patient to infusing genetically modified T-cells into the patient. 
3. To evaluate the two recently approved treatments, Yescarta® and Kymriah®, and 
study their similarities and differences. 
4. To explicate and divulge which are the current trends in CAR-T immunotherapy 
and in what they might evolve in the following years. 
MATERIAL AND METHODS 
This final degree project is based on bibliographic research where databases, official 
websites and some books have been useful to develop this project. 
On one hand, databases such as PubMed and Scopus have been used to search 
information and find scientific articles suitable for the topic of this project. In addition, 
Google Scholar was also used to do a preliminary research, that helped me to make an 
idea of the availability of articles of my interest. Although several scientific articles 
published in various scientific journals were found, in order to guarantee the latest, 
reliable and relevant information, only those articles and reviews most cited and recently 
published were firstly considered.  
On the other hand, search engine from official organizations websites such as the FDA, 
the AEMPS, the EMA and ClinicalTrials.gov were also used to find official assessment 
reports of Kymriah® and Yescarta® and another relevant information. 
Finally, consulting scientific books has been very useful in the development of this 
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RESULTS 
The history of CAR-T cells 
 
 
Figure 8. Historical timeline of the development of CAR T cell therapy. 
Main discoveries and events that led to the creation of CAR T cell therapy as it is known 
nowadays are represented schematically on Figure 8; these historical events will be 
explained in detail in this section. 
In 1960, Eva and George Klein, both tumour biology and cancer immunology’s 
specialists, were pioneers in demonstrating the immune system potential to battle cancer 
cells. Despite of this important role, they did not discover what types of cells were 
implicated. Next year, Jacques Miller discovered the function of the thymus and helped 
to identify thymus derived cells (now known as T-cells). 
From the 60s to the 80s, the main treatment to battle cancer was chemotherapy, 
chirurgical procedure and radiotherapy, but the Surgery Department of National Cancer 
Institution (USA), led by Steven Rosenberg, achieved the first tumour-infiltrating 
lymphocytes treatment successfully [11]. This fact demonstrated the great capacity of 
immune system to treat cancer with your own immune cells. 
In the following decade, scientists started focusing on using retroviral vectors [12] to add 
certain genes into cells to develop new structures or gain different functions: due to that 
new engineering tool, known as gene-transfer techniques, the basis to develop CAR-T 
cells in the future were finally settled. 
First CAR T-cells were developed by Dr. Zelig Eishhar, from the Weizmann Institute of 
Science (Israel), in collaboration with Dr. Steven Rosenberg. They were able to develop 
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and effectiveness were not enough. In the late 90s it was discovered that a co-stimulatory 
sign in CAR T-cells could increase the results: the survival, proliferation and persistence 
were better in that second-generation CAR T-cells. In 2002, that new generation was 
studied targeting directly prostate-specific membrane antigen (PSMA); in that trial, it was 
verified the potential of 2nd-generation CAR T-cells to lyse cells that expressed PSMA 
and the effectiveness of the co-stimulatory molecules [13]. 
One year later, in 2003, a team of scientists modified T-cells in order to express co-
stimulatory signals and targeting CD19 [14], a typical protein in the B-cells membrane. 
In fact, this CD19 is a biomarker for B-cell development but also for lymphoma diagnosis 
and treatment [15]; a T-cell targeting CD19 antigen could reduce B-cell population in 
blood cancer such as ALL and non-Hodgkin lymphoma. 
On April 17, 2012, a 7-year-old girl called Emily Whitehead with ALL enrolled a clinical 
trial after having been treated with several rounds of chemotherapy and not getting a 
good response. A few months later, Emily was the first paediatric patient to be treated 
with CAR-T 19 therapy successfully. 
Finally, after several years of clinical trials, in 2017 the FDA approved two new CAR-T 
19 therapies to treat two different types of blood cancer in paediatric and young adult 
patients: Kymriah® and Yescarta®. This approval changes the entire pharmacological 
and medical paradigm, letting a new path in treatment developments. 
On September 2018, the AEMPS approved those two new treatments and became the 
first CAR-T therapies available in Spain to treat different types of blood cancer. 
Cancer cell therapy 
Adoptive Cell Therapy 
Adoptive cell therapy (ACT) is a potential treatment of several types of cancer that the 
scientific community has been developing since the 80s. As a matter of fact, ACT started 
settling its basis thanks to Steven Rosenberg’s study [11] where lymphocytes were 
extracted from melanomas, expanded in vitro and re-infiltrated into the patient. Those 
tumour-infiltrating lymphocytes were able to achieve the lysis of autologous tumour cells 
and due to that new type of immunotherapy seemed to induce the regression of the 
tumour and produce higher responses. 
Nowadays, ACTs can be classified in three different therapies: 
- Tumour-infiltrating lymphocytes (TIL): a methodology based on extracting T 
lymphocytes from inside of the tumour, activating them and promoting their 
growth thanks to IL-2. Once this T-cell population have grown enough, this T-
cells are re-infused into the patient [16]. 
- Engineered T cell therapy (TCR therapy): This approach is similar to TIL but, 
instead of just isolate T-cells and make them grown, it also involves genetical 
modification in order to express a specific TCR that matches and can recognize 
a certain cancer antigen. Furthermore, it exists the possibility to add additional 
genes, such as certain genes to express cytokines or other proteins to promote 
their survival and proliferation in the body of the patients [17,18]. 
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- Chimeric antigen receptor (CAR) T cell therapy: it is also a strategy that involves 
the genetic modification of T cells, but it does not aim to express a different TCR 
on their surface but to express a recombinant receptor made of two different 
parts: a specific part of an antibody and the internal domain of a TCR [17,18]. 
CAR T cells 
The basic structure of this synthetic receptor consists of three different parts: 
- An extracellular domain, a single-chain variable fragment (scFv or Fv) 
derived from a murine antibody targeting a specific tumour antigen. 
- A transmembrane domain, that makes this structure more flexible to adapt the 
antigen-receptor link and also affects signal transduction. 
- An intracellular domain that plays an essential role in signal transduction and 
function, depending on which CAR generation it is being referred, this domain 
will have different designs [19]. 
As it is explained before, TCR complex only recognize antigens by MHC-mediated 
recognition, but the immunoglobulin structure of the CAR’s antigen recognition domain 
does not require MHC-mediated recognition and it provides to CAR therapy the 
possibility to identify and get linked to a large number of antigens [20]. Even though this 
immunoglobulin fragment provides high affinity and specificity, also only allows to 
recognize cell surface antigens. 
In order to achieve the best results, there have been five generations of CAR cells in the 
past decades [Fig. 9]. Extracellular domain’s structure remains regular and invariable in 
the different generations, but the intracellular domain is always restructuring, adapting 
the intracellular signalling domains to increase the response, avoiding as much as it is 
possible the adverse effects and achieving good clinical results. 
- The first-generation, the simplest of all generations, only combines a single-
chain variable immunoglobulin domain (scFv) and CD3 complex, the same chain 
in T cells receptor. Indeed, this CD3 complex is actually CD3z, and the main 
reason for that is because CD3z has in its structure three ITAM motifs, whose 
activation is the main responsible factor for the stimulation of the signal 
propagation. Thus, this CD3z chain and the ITAM motifs’ phosphorylation, can 
provide the T cell activation, IL-2 secretion, and the enhancing of anti-tumour 
activity and can promote target cells lysis [18]. 
- Once scientist tested this first generation CAR T-cells, they concluded that the 
survival, proliferation and anti-tumour activity were limited in vivo, so they started 
developing a new strategy: adding a co-stimulatory signal to increase the 
potential of this therapy and improve clinic results. A second-generation 
receptor comprises a domain for binding an antigen (scFv), a CD3z cytoplasmatic 
domain for T-cell activation and a co-stimulatory component. It exists a vast 
number of different second-generation designs, depending on what co-
stimulatory domain is being used. Most studied second-generation CAR T cells 
are those whose structure consists of 4-1BB (also known as CD137) or CD28 
signalling domains. In fact, the only two CAR-T cells treatment approved are 
based on these co-stimulatory signals [21]. 
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- So as to further improve, many groups of researchers have designed a third-
generation CAR T cells: this generation is based on second-generation 
receptors but the difference is the incorporation of a second costimulatory 
domain, which helps to drive full T cell activation and proliferation. 
- The fourth-generation of CAR T cells, also known as T cells redirected for 
universal cytokine-mediated killing (TRUCKs), are based on the second and third 
generations but with an additional modification: they are bioengineered with a 
constitutive or inducible expression of a transgenic protein in order to release and 
secrete important substances such as cytokines and promote tumour killing 
thanks to diverse synergistic mechanisms such as exocytosis [22,23]. 
- A fifth-generation of CAR T cells is currently being developed: It is based on 
second-generation CARs structure but it includes a truncated cytoplasmatic 
domain from the IL-2 receptor b-chain with a binding site for STAT3 or/and 
STAT5. Once this T cell is activated by antigen-specific activation, it triggers the 
activation of CD3z, costimulatory domain and cytokine-receptor domain and, 
consequently, it leads to the activation of JAK-STAT3 or/and STAT5 signalling 
pathways. This simultaneous stimulation of those three signals has shown an 
enhance of proliferation, persistence and anti-tumour effects [24,25]. 
 
CD19 CAR Therapy: Kymriah® and Yescarta® 
General information 
The development and design of clinically functional CAR T cell therapy has evolved into 
the creation of bio-immune medicines, also known as gene therapy products, that are 
changing the current cancer treatment situation. 
Recently, in September 2018, two brand new antineoplastic agents have been 
authorized in Spain: Yescarta®, whose active substance is axicabtagene ciloleucel 
(KTE-C19), and Kymriah®, latter is tisagenlecleucel (CTL019). These two medicines 
cancer.44 Although the phase II clinical trials of Canvaxi and
GVAX showed encouraging results, the phase III clinical trials of
both cancer vaccines failed to demonstrat a survival benefit.
Along the same lines, a multipeptide vaccine showed promising
activity in phase I/II trials, paralleled by the induction of immune
responses,45 but the phase III trial failed to achieve its primary
endpoint, presumably due to low immunogenicity.45 These
exemplary results indicate the correlation between the induction
of a specific immune response and benefit to vaccine therapy, but
at the same time question the overall therapeutic benefit of this
approach to treat solid malignancies.46,47 In addition, the need to
enhance T cell activation and persistence has been illustrated by
the unprecedented success rate of trials of therapies that target
immune inhibitory checkpoint proteins such as PD-1.3,4,48 Finally,
many of the aforementioned notions are related to the ability of a
cancer to directly alter its microenvironment, driving immune cell
exclusion and reducing antigen presentation and lymphocyte
activation.49 Based on these experiences and on preclinical
studies, five important concepts have been identified which will
eed to be addressed to employ engineered T cells as a viable
therapy for solid tumours (Fig. 2): improving T cell recruitment to
tumours; e hancing T cell survival and activation; increasing
tumour cell antigen recognition; implementing control strategies;
and counteracting the immunosuppressive microenvironment.
IMPROVEMENT OF T CELL TRAFFICKING TO SOLID TUMOURS
Immune infiltrate is typically low or absent in tumour biopsy
samples from patients who do not respond to immune checkpoint
blockade therapy,18 and is a prognostic factor for poor overall
survival.50 For immune therapy to be effective, effector T cells
need to reach their target cells. Unsurprisingly, if CAR T cells
cannot access their target cells, it is very unlikely that they will be
effective at controlling tumour growth. A recent strategy to
promote immune cell recruitment to tumours takes advantage of
cancer chemokine signalling.50 Chemokines are cytokines with
chemotactic abilities, and are involved in regulating migration and


































Fig. 1 Structure of different chimeric antigen receptor (CAR) generations. a The core structure of a CAR, highlighting the major components
of the extracellular domain, the transmembrane domain and the intracellular domain (endodomain). b Evolution of the development of CARs
from the first generation, which contained only ITAM motifs in the intracellular domain. Second-generation CARs included one co-stimulatory
molecule (CM)1, and third-generation CARs contained a second CM. The fourth generation of CARs was based on second-generation CARs
(containing 1–3 ITAMs) paired with a constitutively or induc bly expresse ch mokine (e.g. IL-12). These T cells are also referred to as T cell
redirected for universal cytokine-mediated killing (TRUCKs). The fifth, or ‘next generation’, is also based on the second generation of CARs,
with the addition of intracellular domains of cytokine receptors (e.g. IL-2Rβ chain fragment). ITAM immunoreceptor tyrosine-based activation
motifs, CD co-stimulatory domain, IL-12 activation of interleukin 12 transcription, IL-2Rβ truncated intracellular interleukin 2β chain receptor
with a STAT3/5 binding motif
Teaching an old d g new tricks: next-generation CAR T cells
N Tokarew et al.
28
Figure 9. Evolution of CAR T cell development [25]. 
  14 
are able to treat and cure B-cell acute lymphoblastic leukaemia (ALL) and two different 
classes of non-Hodgkin lymphomas that are rare cases of hematologic cancer affecting 
B-cells and that is why they have been designated as an orphan medicines. 
As a matter of fact, these two new medicines are synthetic receptors whose extracellular 
domain, formed by an antibody-derived single chain variable fragment, is targeting a 
particular protein on tumour cell surface. In fact, they are designed specifically to 
recognize and get linked to CD19. At the same time, this CD19 protein is used in clinical 
as a biomarker for B cell malignancies, where the vast majority of B-cell related blood 
cancer express normal to high levels of this CD19 antigen [15]. 
The main reason why these two gene therapy medicines have had clinical success lies 
in their structure and mechanism: axicabtagene ciloleucel and tisagenlecleucel are 
second-generation CAR T cells that comprise a CD19-specific scFv region and the 
signalling domains of CD3z and another costimulatory domain, which will be different in 
both immunotherapy products. For example, the intracellular domain of Kymriah® is 
made up by CD3 zeta and 4-1BB as a costimulatory signal domain, while Yescarta® 
includes CD3 zeta and CD28 [26,27]. These structural differences in their costimulatory 
receptor domains will have consequences in their mechanism and transduction signal 
pathways but, despite of this disparity, it will lead to cytolytic activity and cytokine release, 
among others functions, in both cases. 
CD28 and 4-1BB: different costimulatory domains 
CD28 and 4-1BB (or CD137) are intracellular domains often studied and explored as 
checkpoints in immunotherapy treatments because their activation modules several 
aspects such as cellular metabolism, survival and persistence [28-30].  
In a report carried out by an American scientific team in 2016 [31], they tried to 
demonstrate how CAR signalling domains could affect and mediate metabolic 
reprogramming, survival rates cytokines secretion and other important aspects by the 
activation of different signalling pathways and find an explanation in the observed 
differences in clinical efficacy for Kymriah® and Yescarta®. They found that 4-1BB CAR 
T cells can increase central memory T cells’ (TCM) population, mitochondrial biogenesis 
and oxidative metabolism. On the contrary, CD28 plays an important role in increasing 
effector memory T-cells (TEM) and aerobic glycolysis. 
CD28 induces the expression of Glut1, which is an important transporter involved in 
glucose uptake, and enzymes such as PDK1: both molecules were found in higher 
proportion in CD28 cells compared to 4-1BB CAR T cells. Another example found was 
the increase of essential enzymes related to the breakdown of glucose during the 
glycolytic pathways that achieve higher levels in CD28 cells than in 4-1BB cells. They 
also found that mitochondrial biogenesis and fatty acid oxidation were significantly higher 
in 4-1BB CAR T cells than in CD28 cells. All those discoveries suggested that CD28 
CAR T cells tend to rely on a glycolytic metabolism, whereas 4-1BB T cells use oxidative 
breakdown of fatty acids as an energy source. 
It is known that, after triggering CAR T cells, it could occur class switching and evolution 
into memory cell that are critical in the long-term persistence and that it is the key for a 
good immunotherapy treatment. In fact, this study provides solid evidences which 
corroborate that CAR T cells with CD28 as a costimulatory domain tend to be less 
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persistent than the ones using 4-1BB signalling domain because of their metabolic 
reprogramming: CAR T cells that increase proliferation and persistence enhance 
oxidative metabolism and that is characteristic of TCM, whereas T cells with aerobic 
glycolysis is common in TEM and that is the reason why its persistence is less [32,33]. 
As it can be seen, Figure 10 highlights the main actions caused by this two different 
costimulatory cytoplasmatic domains in CAR T cells; despite of this slightly differences 
in the mechanism and process, the final achievement is the activation of T cell response 





Kymriah® and Yescarta® are indicated for the treatment of different types of blood 
cancer, mainly in paediatric and young adult population, but also in adults; depending on 
what disease we want to treat and the patient’s condition, one or another will be properly 
indicated. Despite of the different types of B-malignancy, what they have in common is 
that they are CD19+. 
In order to have a global view of these gene therapy products, their importance in clinical 
treatment and understand exactly how they can treat these diseases, it is essential to 
possess certain knowledge about these blood disorders. 
B-cell acute lymphoblastic leukaemia (ALL) 
This type of blood cancer is caused by a somatic mutation in one pluripotent 
hematopoietic stem cell and that mutation triggers clonal proliferation. This gene 
transformation will have bad consequences on this stem cell differentiation and, thus, 
the development of mature cells will not occur. ALL is the most common type of blood 
Figure 10. CAR T cells containing 4-1BB or CD28 signalling 
domains and their respective consequences: BBz CAR cells are the 
ones with 4-1BB domain and 28z CAR cells possess CD28 as a 
costimulatory domain [31]. 
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cancer in children and adults younger than 20 years (60% of cases) and its most 
common manifestations are caused by the accumulation of malignant, not differentiated 
lymphoid cells (lymphoblasts) that can be found mainly in the bone marrow, but also they 
can be present within different organs such as the spleen, liver and lymphatic nodes, 
through a process called organ infiltration [34].  
Kymriah®, whose active substance is tisagenlecleucel, is indicated for the treatment 
of this haematologic malignancy when the patient is a child or young adult up to 25 years 
old with B-cell ALL that is refractory (when leukaemia reappears after a period of 
remission), in relapse (when the disease does not respond to treatment) after a 
transplant of stem cells or in second or later relapse. This condition is also described as 
r/r B-cell ALL.  
Diffuse large B cell lymphoma (DLBCL) 
DLBCL is one of the most common aggressive non-Hodgkin lymphomas (nearly 40% of 
non-Hodgkin lymphomas in adults). As a lymphoma, lymph nodes, spleen and other 
organs are affected, unlike leukaemias, which usually are present in circulating blood 
cells and bone marrow. Commonly, it is caused by the development and growth of a 
previous lymphoma or its origin may be caused de novo as a result of certain gene 
modifications [35]. 
Kymriah® and Yescarta® are indicated to treat adult patients with refractory or relapse 
diffuse large B-cell lymphoma, when the patient has been treated with two or more 
systemic therapies. 
Primary mediastinal large B cell lymphoma (PMLBCL)  
This third type of haematological cancer is an uncommon disease with a relative 
frequency around 3% of B-cell non-Hodgkin lymphomas and it is conceived as a subtype 
of DLBCL, constituting 6% of the cases in this group. Generally, it affects young adults 
population (between 30-35 years) with a female predominance. It is characterized by a 
diffuse proliferation of large B-cells within sclerotic tissue and it tends to get 
compartmentalized, facts that are observed as an invasive mediastinal mass [36]. 
Yescarta® is the one indicated to treat this disease in adults patients with refractory or 
relapse PMLBCL that have been treated with two or more lines systemic therapy. 
Manufacturing of CAR-T cells 
The production of CAR T cells is a complex and difficult process that requires a 
reproducible T cell manufacturing platform and proper gene-editing and gene-transfer 
tools in order to achieve the suitable CAR T cells characterization and quality. Several 
studies and investigations have been necessary to obtain a procedure and a protocol 
that suit perfectly to the main objective: obtaining the correct number of engineered CAR 
T cells that will have the desired clinical response once they are re-introduced into the 
patient [Fig.11]. 
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Figure 11. CAR-T cell manufacturing process. Adapted from [26]. 
Leukapheresis, preservation and transport 
As an autologous therapy, the manufacturing process of CAR T cells begins with 
leukapheresis collection and its transportation. Leukapheresis is a clinical procedure 
during which blood is withdrawn from the patient’s body and peripheral blood 
mononuclear cells (PBMC), including T-cells, are collected. The remaining blood and its 
non-necessary components are re-infused into the patient. This isolated PBMC are 
transported and arrive to the central manufacturing facility where the production of 
tisagenlecleucel or axicabtagene ciloleucel takes place [17,26]. 
Before being shipped to the manufacturing facilities, leukapheresis material is 
cryopreserved within 24 hours after collection and it is stored under -120ºC surrounded 
by a cryomedium environment that guarantees the availability of cells. This 
cryopreservation allows for early leukapheresis because it is possible to store this frozen 
material up to 30 months before the manufacturing process begins and the quality of the 
sample remains stable during this long period [37-38]. 
Manufacturing process: genetic engineering. 
Once the samples of the patient are in the laboratory, T cells in the incoming 
leukapheresis will be processed slightly different depending on the drug manufacturing 
protocol, but all these different ways of proceeding share some common steps. Firstly, 
the patient leukapheresis material is needed to be defrosted under certain conditions 
and washed to remove the cryogenic solution [38]. Therefore, T cells are enriched and 
activated before being genetically modified by retroviral vector transduction; during this 
enrichment and activation, T cells become more receptive to transduction, making easier 
to modify their genes successfully [39]. 
The viral vectors used in this type of gene-editing and transduction procedures are 
gamma-retroviral and lentiviral vectors because, among viral vectors, they have proofed 
being the most efficient and they are able to integrate transgenes that will remain stable 
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in the host genome and their toxicity is lower than any other viral vector. These gamma-
retroviral and lentiviral vectors are derived from retroviruses and lentiviruses 
respectively, which are subtypes within the Retroviridae family. This type of virus 
possesses the ability to transcribe its RNA genome into cDNA reversely, and that would 
be the key to the integration of the vector genome into the genome of the T cells. In 
addition, these viral vectors have lost their capability for self-replicating but not their 
ability to integrate the synthetic genes located inside them, in this case the CAR gene, 
into the T cell genetic material. The axicabtagene ciloleucel manufacturing utilizes a 
gamma-retroviral vector, where transduction occurs at least 48 hours after the activation; 
tisagenlecleucel manufacturing process is developed by a lentiviral vector, with which it 
is possible to initiate the transduction phase 24 hour after T cell activation [39,40]. 
Once T cells have been enriched and activated, this activation leads to the transportation 
of certain proteins that will be re-ubicated on the plasma membrane surface and the 
expression of this surface ligands improves success of the transduction process. As a 
consequence of this process where synthetic DNA (anti-CD19 CAR gene) is inserted 
into the T cell genome, this cells become chimeric T cells that express a new form of 
receptor that targets CD19 and whose endodomain is different depending on the 
targeting immunotherapy, as previously explained. This chimeric gene integration 
process last 24 hour until is completely done [26]. Following genetic CAR engineering 
modification, CAR T cells are expanded in a bioreactor in order to achieve the final dose. 
As it can be seen in Fig. 12, the initial cell population of the patient’s leukapheresis 
material is evidently different than the final product, which represents a strong evidence 







Even though this graphic represents the difference between initial leukapheresis material 
and final product composition during ELIANA clinical trial (where tisagenlecleucel was 
tested), the current final product composition for both immunotherapies is very similar to 
the image portrayed in the previous figure [38]. 
After CAR T cell expansion it is required rigorous and robust quality testing so as to verify 
that this CAR T cell production has been developed following the stablished and current 
GMP (Good Manufacturing Practices): the control of final product bags composition, their 
safety, microbiological presence and others parameters that once were stablished during 
their clinical trials and they help to ensure quality, security and effectiveness [41,42]. 
The final step before leaving the central manufacturing facility is cryopreservation of the 
final product bags in order to maintain all the quality parameters and ensure that the final 
Figure 12 . Cell population differences between initial and final product, focusing in this example on 
tisagenlecleucel [38]. 
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product that will arrive to patients has the same characteristics as when the products 
bags left the manufacturing laboratories. 
During this entire manufacturing process, it is essential to maintain the chain of identity 
due to Kymriah® and Yescarta® are autologous immunotherapies and these medicines 
are made from the blood of patients so it must be ensured that patients are treated with 
their own medicine. To guarantee this traceability and ensure this chain of identity, these 
companies have developed different protocols and tools, using a unique patient ID, to 
identify and localise where exactly is the material of patients after leukapheresis, 
manufacturing and during transport.  
Administration into patients: pharmaco-clinical protocol 
The administration of this type of immunotherapy treatment requires a certain 
pharmacological and clinical conditions so as to achieve an early and sustainable 
response (minimum 18 months) and guarantee the survival of the patients because of 
the administration of this medicine. General considerations and criteria are slightly 
different depending on the B-malignancy treated and the CAR T therapy that is being 
used. 
Use of tisagenlecleucel and axicabtagene ciloleucel for DLBCL 
• Patient selection criteria: the patients that will be under this treatment must 
accomplish all of this requirements, that comprise being 18 years old or more, 
histological diagnosis that certifies the presence of DLBCL and it is must be 
confirmed the presence of refractory or relapse disease, diagnosed by a biopsy. 
In addition, patients’ situation must fit in the Yescarta® and Kymriah®‘s 
indications that have been described previously. 
Cardiac, pulmonary, renal and liver functions must be checked to ensure a good 
management and tolerability of the treatment. Also, it exists certain situations that 
do not allow this treatment, for instance having uncontrolled autoimmune 
diseases, patients that are infected with hepatitis B or C and having been treated 
with another CAR T therapy, among other situations. 
• Optimum dose: Both medicines are available in cell suspension for infusion 
containing a specific concentration of CAR T cells. The dose of axicabtagene 
ciloleucel is 2·106 viable CAR-T cells per kg of body weight with a maximum dose 
of 2·108 viable CAR-T cells for those patients whose body weight is over 100 kg. 
The dose of tisagenlecleucel is non-weight-based dosing that comprises a 
suspension ranging 0’6-6·108 viable CAR-T cells [43]. 
Use of tisagenlecleucel for B-ALL 
• Patient selection criteria: the treatment for B-ALL using tisagenlecleucel is 
indicated paediatric patients and young adults up to 25 years old and having a 
B-ALL refractory or relapse. Other specifications that must be accomplished are: 
confirming the expression of CD19 in cancerous cells by flow cytometry and the 
function of the main organs, such as kidney, lungs, liver and heart must be 
enough so as to tolerate the treatment.  
On the other hand and similar to the treatment of DLBCL, there are situations 
where tisagenlecleucel would not be appropriated and it would not be allowed, 
such as syndromes where bone marrow is damaged or patients with active virus 
infection (hepatitis B or C or HIV), among other situations. 
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• Optimum dose: dosing of tisagenlecleucel is body weight based for patients that 
weigh 50 kg or less, ranging 0’2-5’0·106 CAR-T cells per kg of body weight. Unlike 
the previous situation, if the patient’s weight is over 50 kg, the dose is non-weight-
based and it comprises 0’1-2’5·108 CAR-T cells [44]. 
Prior treatment and post-administration monitoring 
While tisagenlecleucel or axicabtagene ciloleucel is being developed and manufactured, 
it is required the patient to undergo a conditioning chemotherapy. Fundamentally, this 
lymphodepleting chemotherapy uses cytotoxic drugs that plays an important role in 
enhancing the CAR T cell immunotherapy activity, effectiveness and success rate. 
During clinical trials many combinations of this cytotoxic drugs have been used, but the 
ones that have proofed an improvement are the ones that are approved currently: 
depending on what it is being treated and the immunotherapy used, the lymphodepleting 
pre-treatment, dosing and duration will be different [26]. 
The main purpose of the lymphodepleting chemotherapy required before 
tisagenlecleucel infusion for the treatment of DLBCL is achieving a leucocyte count of 
1.000 cells/µL or less within a week prior to treatment. If, by any circumstance, 
tisagenlecleucel infusion delays over 4 weeks and the white cell count of the patient is 
over 1.000 cells/µL, it would be required another lymphodepleting chemotherapy 
treatment. It is recommended fludarabine (at a dose of 25 mg per square meter of body-
surface area) and cyclophosphamide (250 mg/m2) daily for 3 days. On the contrary, it is 
recommended fludarabine (at a dose of 30 mg/m2) and cyclophosphamide (500 mg/m2) 
during the fifth, fourth and third day prior axicabtagene ciloleucel infusion for the 
treatment of DLBCL [43].  
For the prior treatment of B-ALL with tisagenlecleucel comprises fludarabine (30 mg/m2 
daily for 4 days) and cyclophosphamide (500 mg/m2) for two days starting at the same 
time as fludarabine infusion [44]. 
The mechanism which fludarabine and cyclophosphamide have a positive impact in the 
CAR T cell treatment is currently being discussed and explored, but it has been proofed 
that this lymphodepleting is able to inactivate regulatory T lymphocytes, enhance the 
presence of APCs and their activation, change the cytokine environment: for instance 
increasing pro-inflammatory cytokines and T cell activating cytokines such as IL-15. 
Despite of the fact that this successful mechanism is not entirely comprehended, this 
prior treatment is essential to achieve an optimal and favourable environment to CAR T 
cells’ survival, expansion, and, consequently, effectiveness [26,45]. 
Once the plastic bags, that contain the engineered CAR T cells, arrive to the hospital or 
treatment centre where the treatment will be infuse, the CAR T cells of the patient are 
thawed and then infused into the patient. This should be done in a hospital setting where 
the doctors can monitor the patient for side effects and toxicity. Depending on body 
patient’s reaction, it will be necessary to stay in or leave the hospital centre and return a 
few days after. 
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Common toxicities of Kymriah® and Yescarta® 
As it can be guessed due to their structure, axicabtagene ciloleucel and tisagenlecleucel 
are anti-CD19 CAR T cells therapies that possess similar mechanism of action so they 
will share common toxicities. It is important to clarify and understand their mode of action 
to comprehend their side effects: once these medicines are infused, the expansion of 
CAR T cells happens during first 1 or 2 weeks after the infusion and after this event 
follows the optimal long-term persistence. It has been proofed that certain biomarkers 
such as different cytokines achieve higher levels as a response to expansion, cytotoxicity 
and persistence [26]. Actually, these engineered-modified T cells are designed to 
recognize one specific antigen: CD19. Thus, these immunotherapies will have effects on 
the entire B cell lineage, producing a reduction of population of normal B-cells and 
neoplastic B-cells indistinctly. 
Regarding side effects, the most important toxicities are cytokine release syndrome 
(CRS) and neurologic events or neurotoxicity. It is believed that these side effects are 
related to their mechanism of action, despite of the fact that these toxicities are not 
practically comprehended. Thus, there are not current prevention treatments to avoid 
these side effects, only palliative measures and immunosuppression are the only 
available treatments [46]. 
Cytokine release syndrome 
CRS is one of the most common side effects with an incidence greater than fifty per cent 
of patients. This life-threatening toxicity is caused by the high levels of cytokines released 
by T cell activation once CAR T cells recognize CD19 antigen in tumour cells and that 
triggers their activation and expansion. Both activated T cells and immune cells such as 
monocytes or macrophages secrete a range of cytokines and chemokines that will cause 
symptomatology such as fever, nausea, fatigue or myalgia. These symptoms could 
evolve to several hypoxia or vital organs affection that could put in danger patient’s life. 
Indeed, these cytokines and chemokines are used as a biomarker to anticipate the 
magnitude of the CRS that will appear once the patient is infused: if high levels are found 
before or one day after infusion, this situation is associated with a future severe CRS 
[47]. According to [48], there are four different grades of CRS depending on vital signs, 
different parameters, symptomatology and its severity. For this reason, it is essential 
monitoring the patient after CAR T cell infusion, for at least seven days, with a total 
monitoring including vital signs, physical examination and blood count. 
The symptomatology during grade 1 is managed with symptomatic treatment only, for 
instance, if the patient develops fever, will be treated with paracetamol or ibuprofen. In 
case of the patient’s oxygen requirements are less than 40% of fraction of inspired 
oxygen, it would be an affectation within grade 2 that would be treated with intravenous 
tocilizumab. Tocilizumab is a monoclonal antibody anti-IL6-receptor (IL-6R); this 
election is because IL-6 levels and CAR T cells levels are related to intensity of CRS. 
Actually, what IL-6 does is interacting with several cell types (not only immune cells), 
enhancing pro-inflammatory response and, consequently, developing CRS. Even though 
tocilizumab is only approved for the treatment of rheumatoid arthritis, the off-label use of 
tocilizumab helps to manage moderate-to-severe CRS episodes. Corticosteroids 
usage is also contemplated when CAR T cells toxicities are still uncontrolled after 
intravenous tocilizumab. The reason why corticoids are last-line treatment is because, 
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despite of the fact that they have anti-inflammatory activity, they also are able to reduce 
T cell function and enhance T cell apoptosis [47]. 
In addition, some studies have shown that the timing of CRS appearance is related to 
the CAR structure used: those CAR T cells made up by CD28 as a costimulatory domain 
(axicabtagene ciloleucel) tend to develop CRS earlier than if it is used CAR T cells with 
4-1BB as a costimulatory domain (tisagenlecleucel).  
Neurotoxicity 
CAR T-cell related encephalopathy syndrome (CRES) is the most common 
neurological toxicity in CAR T cells infused patients, characterized by handwriting 
problems, confusion, delirium and disorientation, but could evolve into life-threatening 
symptoms such as tremors or cerebral oedema that could increase intracranial pressure. 
It is observed that CRES manifestations has two different phases: the first one occurs 
during the five days post-infusion, at the same time CRS symptoms; the treatment of this 
first phase requires tocilizumab. The second phase usually is manifested after five days 
post-infusion, when fever and CRS symptoms cease. Actually, seizures and delirium 
episodes happen during third or fourth week after CAR T cell infusion and this delayed 
toxicities within second phase have better response to corticosteroids. Even though 
there are different grades of CRES depending on symptoms, signs and vital parameters 
and, thus, patient’s condition can be treated concretely, CRES status can change rapidly 
so it is essential having the patient monitored. 
Main causes of CRES remain unclear, but several studies pointed out that this 
neurological side effect could be caused by an increasing of cytokines’ presence in the 
brain (for instance, high levels of IL-6 have been found) but also the presence of T cells 
into Central Nervous System (CNS) could be responsible for these sever neurologic 
events. 
In addition, some of the symptoms and signs of CRS and CRES could happen 
simultaneously so it is important a strong medical judgment in order to discern between 
them and also differentiate between CAR T cell related side effect and other concurrent 
medical conditions [47]. 
National approach: situation in Catalonia 
Current situation 
Axicabtagene ciloleucel (Yescarta®) from Kite Pharma, a Gilead’s company, was the 
first CAR T therapy authorized in Spain on 6th September 2019, although the second 
CAR T therapy approved and funded by the Ministerio de Sanidad, Consumo y Bienestar 
Social (MSCBS). On the other hand, tisagenlecleucel (Kymriah®) from Novartis was 
authorized in Spain on 17th September 2018 by the AEMPS; despite of being the second 
CAR T cell therapy approved, Kymriah® became the first CAR T therapy funded by the 
MSCBS. 
This means that, despite of being high-cost immunotherapies, patients whose B cell 
malignancies (B-ALL, DLBCL or PMLBCL) have been treated several times with non-
satisfactory results, they have another opportunity to be treated and try to give hope to 
these cases that didn’t have any other treatment. 
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In Spain there have been designated 11 hospital centres where CAR T cell therapy can 
be used; depending on which specialised setting they can provide (for instance, 
paediatric specialist centre or not) certain used of this CAR T cell therapy will be allowed. 
In addition, there are three hospital centres with an exceptional use in case of the 
designated health centres have an amount of activity that exceeds their management. 
Particularly in Catalonia, there are four hospital centres where these kind of treatments 
are being administrated: Hospital Clínic, Hospital de la Santa Creu i Sant Pau, Hospital 
Vall d’Hebron, Hospital Sant Joan de Déu. Each one is specialised in the treatment of 
patient of different ages and diseases, for instance, and more remarkably, Hospital Sant 
Joan de Déu was the first hospital centre in treating a B-ALL paediatric patient with CAR-
T therapy (Kymriah®), the first treatment promoted by the Sistema Nacional de Salud 
(SNS) [49]. Indeed, Hospital Sant Joan de Déu was the first Spanish paediatric hospital 
being accredited to administrate and use this individualised therapy; from that day until 
2019 this hospital centre has infused 39 paediatric patients with CD19 CAR-T therapy. 
These facts emphasise how relevant and pioneering is this hospital in leukaemia and 
oncology treatments [50]. 
Banc de Sang i Teixits: cell-processing laboratory. 
The manufacturing process of these two individualised immunotherapies is slightly 
different in Catalonia due to the intervention of Banc de Sang i Teixits (BST) in this 
process. The BST is a public agency of Departament de Salut de la Generalitat de 
Catalunya that, among other important functions, has an active role in the Kymriah®’s 
and Yescarta®’s manufacturing process. BST is responsible of the leukapheresis 
material reception and quality control, cryopreservation and distribution. 
Fortunately, I had the opportunity to talk with a laboratory technician that works in the 
BST, concretely in the Cell Therapy Unit, where it is processed the leukapheresis 
material after its collection. She explained to me how the material is processed, the 
requirements demanded and the protocols their team follow in order to achieve an 
appropriate modus operandi.  
Actually, the BST important role is obvious since the beginning of the whole 
manufacturing process: the leukapheresis collection occurs in leukapheresis collection 
units related to BST; for instance, the collection of patients from Vall d’Hebron takes 
place in BST-Vall d’Hebron unit. 
When leukapheresis material of the patient is sent to BST central facilities, it is received 
in the cell processing laboratory where cell counting and quality control are performed: 
the samples must accomplish what the manufacturing laboratories demand so one of 
the BST’s mission is adjusting these samples into the reference ranges demanded. For 
instance, BST laboratory technicians adjust total nucleated cell (TNC) count and the 
CD3+ presence in leukapheresis samples before the material is frozen.  
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As shown in Figure 13, these are the 
reference values that Novartis requires 
before the cryopreserved material is 
sent to the manufacturing facilities. If 
the samples do not fit manufacturer’s 
requirements, it is necessary to reduce 
the volume and adjust the values 
thanks to Sepax Cell Separation 
System, which is an automated system 
that processes blood samples and other 
cellular products and separates cells. In 
fact, this cell processing system is 
coordinated by a protocol software 
called PeriCell. This software is 
specially designed for plasma reduction 
of apheresis products in order to 
achieve a reduced volume of the 
samples; it is produced two different 
bags, one containing the cell extraction, which will be highly concentrated, and the other 
containing plasma residues. 
While this cell concentration is being performed, cryopreservation solution is prepared, 
containing 30% of Viaflo Plasmalyte 148 (pH 7,4), 40% of Human Serum Albumin (HSA), 
10% of ACD-A (anticoagulant citrate dextrose solution A), which is an anticoagulant 
solution for apheresis products, and 20% of a cryoprotectant called DMSO (dimethyl 
sulfoxide). 
Once the cell concentrate bag is obtained, this bag and the cryomedium solution are 
mixed and added by an automatic device called Smart-Max that can prepare cellular 
products for cryopreservation.  
Finally, seven sample tubes (known as sentinel vials) are collected from this final 
solution: four of this cryovials will be sent next to the cryopreserved leukapheresis 
material to manufacturing facilities and the other three will be used to measure cellularity 
of the sample; that helps to confirm that every step of this cellular processing and 
cryopreservation have been realised successfully.  
The final step of this cell-processing procedure is cryopreservation: first, the cryobags 
and sentinel vials are frozen in a controlled-rate freezer. When the temperature is -80ºC 
or below, subsequent storage takes place in a vapor phase liquid nitrogen tank where 
temperature required is -120ºC or below. After a minimum of 8 hours remaining in this 
conditions, cryopreserved leukapheresis materials are completely ready for their 
shipment and delivery to Novartis or Kite manufacturing facilities. The BST also receives 
the final product coming from manufacturing laboratories and BST delivers the frozen 
final product to hospital facility where infusion into patient will be performed. 
Furthermore, autologous products as tisagenlecleucel and axicabtagene ciloleucel 
require that cells collected from one patient must be infused into the same patient so 
preserving chain of identity is essential to track and verify all materials. In order to ensure 
safety and accurately identify patient material, unique patient identifiers are used at each 
Figure 13. Screenshot taken from a computer monitor in BST facilities. 
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step in the process. The identifiers used to ensure traceability are patient name, date of 
birth and apheresis ID. This apheresis ID comprehends two different codes: Donation 
Identification Number (DIN), a code assigned by the International Society of Blood 
Transfusion (ISBT) that helps to identify each collection event (for BST the code starts 
by E0025, code also known as Facility Identification Number, FIN). On the other hand, 
there is the Single European Code (SEC), that helps to identify any tissues or cells 
donation in the European Union. As a curiosity, this code ends by the expiry date. All 
these codes and patient data must be visible in the label of the cryobags and cryovials. 
Step into the future 
Developing autologous CAR T-cell therapies, such as Kymriah® and Yescarta®, has 
become one of the most promising immunotherapies and their success has motived the 
exploration of new scientific paths so as to integrate this CAR T cell concept into other 
applications.  
From autologous to allogeneic 
Being an autologous therapy implies avoiding allogeneic reaction such as human 
leucocyte antigen (HLA) disparities between the donor and the recipient, increasing the 
safety of the treatment and that provides moderate-to-long term persistence. On the 
other hand, autologous therapy is synonym of individualized treatment that requires a 
good leukapheresis material from the patient whose quality may be non-optimal due to 
patient’s characteristics and previous treatments, and a unique manufacturing process 
which lasts three weeks on average, something negative for patients with advanced and 
severe disease. 
In allogeneic CAR T cells, the origin of the donor would be a healthy donor whose 
immune system cells have not suffered negative consequences of cancer and 
chemotherapy treatments, so allogeneic CAR T cells’ quality would be greater. Even 
though the risk of suffering graft-versus-host disease (GVHD) in allogeneic treatments is 
really high, gene-editing techniques are being developed and used so as to inhibit host 
immune system’s reaction.  
In addition, it exists the possibility of creating a cell bank depending on the expression 
of HLA, in order to avoid HLA disparities, and also having different CAR T cells targeting 
different antigens so it would be possible to embrace different diseases. Similarly to 
autologous CAR T cell manufacturing process, leukapheresis material from healthy 
donor would be transported to manufacturing facilities where these T cells would end 
genetically modified and posteriorly cryopreserved but, unlike autologous CAR T cells, 
modified T cells could be stored in cell banks until a patient requires them. 
This allogeneic CAR T cell concept is becoming an incredible promising idea with 
multitude of future applications; this potential is currently being explored, as can be seen 
in all the existing clinical trials with allogeneic CAR T cells targeting different antigens 
(the vast majority in preclinical phase) [51]. 
Solid tumours 
Applying CAR T cell therapy to treat solid tumours is currently being a massive challenge 
for scientific community because CAR T cells as are known nowadays have not proofed 
being useful for solid tumours. Thus, CAR T cell therapy’s limitations are being explored 
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and analysed so as to address new approaches to achieve robust therapeutic benefit in 
solid tumours. Following information highlights the main challenges and factors to 
overcome that require to be studied in order to achieve clinical success in treating solid 
tumours: 
Unlike B-cell malignancies that express high levels of specific antigens on their surface 
such as CD19, solid tumours derived from neural or epithelial tissue express a large 
number of surface antigen which are also expressed in high levels in normal tissues. 
Gene-editing modification to recognise several surface antigen are being developed so 
as to overcome solid tumours’ heterogenicity and, this way, reducing on-target off-
tumour toxicity could also be resolved. Due to specific location of solid tumours, the CAR 
T cells’ presence is limited so enhancing their migration and a local administration of the 
therapy may help to overcome this issue. Also, tumour microenvironment may decrease 
T cell activity so CAR T cells need to inhibit this suppressive environment by secreting 
cytokines and checkpoint inhibitors. 
However, these strategies are currently being developed and ongoing clinical trials could 
make possible to expand CAR T cells treatments beyond B-cell malignancies and their 
progress and efficacy might be seen sooner than is expected [52]. 
DISCUSSION 
This revolutionary individualized immunotherapy that targets CD19 antigen on B-cell 
lineage has helped to treat hopeless cases of leukaemias and B-cell malignancies, 
restoring hope in those cases where patients had been treated before without reaching 
a complete success. Progress in scientific, biological and pharmacological fields have 
culminated into the development of this innovative autologous immunotherapies, CAR T 
cells, that act as a booster of host’s immune system, enhancing its intrinsic anti-tumour 
activity and achieving short- and long-term effects. 
Recently, two different types of CAR T cell therapies have been approved by the FDA 
and the AEMPS: Kymriah® and Yescarta®, becoming an important paradigm shift due 
to their special characteristics. Because of their structure, mechanism of action and 
intrinsic factors of the patient (the vast majority of them still remain unknown), their 
clinical data and response are different in each patient. Nevertheless, from a general 
point of view their clinical data is interpreted as positive and successful. 
Tisagenlecleucel was tested in a multicentric phase II clinical trial called ELIANA where 
paediatric and young adult patients were treated for ALL r/r [53]. The overall remission 
rate was 81% (95% CI) and the complete remission rate was 60% of the patients; the 
median response duration was not reached. In addition, tisagenlecleucel was tested in 
a multicentric phase II clinical trial called JULIET where adults with DLBCL r/r were 
treated, obtaining the following data: the overall remission rate was 52% (95% CI) and 
the complete remission rate was 40% of the patients and after 14 months since infusion, 
the median response duration was not reached [54]. 
On the other hand, a multicentric, phase II clinical trial known as ZUMA-1 was performed 
in patients with DLBCL r/r to test axicabtagene ciloleucel. The overall response rate was 
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82% (95% CI), the complete response rate was 54% and the median response duration 
was 11,1 months [55]. 
As it can be seen in the data exposed, the median response duration is achieved on 
axicabtagene ciloleucel clinical trial whereas on JULIET and ELIANA trials is not. This 
situation could be intimately related to their intracellular structure, where costimulatory 
domains had an important role in long-term persistence, among other factors. 
Even though these immunotherapies have common indications and it might seem 
possible to compare, limitations, bias and inherent factors of each clinical trial handicap 
an effective comparison. Anyway, post-authorisation studies are required in order to 
obtain long-term safety and effectiveness data and being able to provide a clear view of 
their safety, effectiveness and efficiency. 
In conclusion, it must be highlighted that, although CAR T cells therapies have proofed 
their effectiveness and good clinical results, moderate-to-severe side effects and the 
manufacturing, logistic and monetary aspects are challenges that must be overcome in 
the future. For instance, allogeneic CAR T cells, improving CAR T cell designs, reducing 
side effects and studying new targets are paths that should be explored in the future so 
as to become what it is expected from this immunotherapies: the perfect weapon against 
cancer. 
CONCLUSIONS 
1. Nowadays, axicabtagene ciloleucel and tisagenlecleucel have become one of the 
most promising immunotherapies in those cases where B-cell malignancies have 
turned refractory or relapsed and any treatment is no longer available. 
2. There are many factors that modify safety and effectiveness, such as CAR T cell 
design, leukapheresis material, prior treatments and intrinsic factors of the 
patients such as immune system response.  
3. Side effects have been noticed to be frequent: CRS and CRES are present in at 
least 50% of treated patients. Their cause is still being understood and studied 
so it is indispensable to find biomarkers that could be used as correlative factors 
in order to prevent and anticipate these toxicities. 
4. New approaches are currently being studied so as to develop their full potential, 
such as allogeneic CAR T cells, and also apply this CAR T cell concept into new 
medical areas such as solid tumours, which seems to be really promising. 
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